Jpmorgan Chase & CO Kamada LTD Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KMDA
# of Institutions
33Shares Held
5.67MCall Options Held
300Put Options Held
151K-
Phoenix Holdings Ltd. Givatayim, L31.92MShares$9.88 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.33MShares$6.82 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny847KShares$4.36 Million0.01% of portfolio
-
Wells Fargo & Company San Francisco, CA625KShares$3.22 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA441KShares$2.27 Million0.01% of portfolio
About KAMADA LTD
- Ticker KMDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 44,800,500
- Market Cap $231M
- Description
- Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...